Immunic, Inc.
IMUX
$1.19
-$0.02-1.25%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.08% | 37.30% | 27.23% | 2.86% | -2.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.99% | 1.04% | 18.71% | 12.33% | 9.62% |
| Operating Income | 8.99% | -1.04% | -18.71% | -12.33% | -9.62% |
| Income Before Tax | 23.34% | -4.97% | -25.44% | 13.90% | -16.70% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 23.34% | -4.97% | -25.44% | 13.90% | -16.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 23.34% | -4.97% | -25.44% | 13.90% | -16.70% |
| EBIT | 8.99% | -1.04% | -18.71% | -12.33% | -9.62% |
| EBITDA | 9.03% | -1.05% | -18.68% | -12.27% | -9.58% |
| EPS Basic | 60.28% | 45.18% | -28.80% | 7.04% | 48.32% |
| Normalized Basic EPS | 63.76% | 45.15% | -28.81% | -3.52% | 48.33% |
| EPS Diluted | 60.28% | 45.18% | -28.80% | 7.04% | 48.32% |
| Normalized Diluted EPS | 63.76% | 45.15% | -28.81% | -3.52% | 48.33% |
| Average Basic Shares Outstanding | 92.96% | 91.46% | -2.59% | -7.35% | 125.80% |
| Average Diluted Shares Outstanding | 92.96% | 91.46% | -2.59% | -7.35% | 125.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |